A phase II trial of 506U78 (IND 52611) [nelarabine] in patients with relapsed or refractory non T-cell acute lymphoblastic leukemia (ALL).

Trial Profile

A phase II trial of 506U78 (IND 52611) [nelarabine] in patients with relapsed or refractory non T-cell acute lymphoblastic leukemia (ALL).

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jan 2012

At a glance

  • Drugs Nelarabine (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top